U.S., AstraZeneca strikes an antibody treatment USD 486 million deal
The U.S. government awarded the pharma giant AstraZeneca a sum of USD 486 million for the development of up to 100,000 corona vaccine doses. The deal, under Operation Warp Speed, will people the manufacturing of antibody doses and facilitate the smooth conducting of Phase III trials.
AstraZeneca’s antibody treatment, although, is similar to Regeneron’s antibody cocktail treatment, however, its vaccine, which is a combination of two LAABs derived from patients who recovered from COVID-19, has the potential to not only treat but also prevent the spread of the virus in already infected COVID...
